- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00723203
Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
A Phase II Study of LBH589, a Novel Histone Deacetylase Inhibitor, in Relapsed and Refractory Adult Patients With Acute Leukemia (AL) or in Newly Diagnosed Patients Over the Age of 60
RATIONALE: Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying the side effects of panobinostat and to see how well it works in treating patients with relapsed or refractory acute lymphoblastic leukemia or acute myeloid leukemia.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
OBJECTIVES:
Primary
- To determine the antitumor activity of panobinostat, in terms of objective response rate, time to progression, and survival, in patients with relapsed or refractory acute lymphoblastic leukemia or acute myeloid leukemia.
- To assess the toxicity of panobinostat in these patients.
Secondary
- To perform correlative laboratory studies to assess changes in various proteins that may be altered by histone deacetylase inhibition therapy.
OUTLINE: Patients receive oral panobinostat once on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Patients undergo peripheral blood and bone marrow sample collection at baseline and on day 28 of course 1 for correlative laboratory studies. Samples are analyzed by RT-PCR for reactivation of FANCG, FOXO3A, GADD45A, GADD45B, GADD45G, H2AX, and TP73.
After completion of study treatment, patients are followed for at least 4 weeks.
PROJECTED ACCRUAL: A total of 74 patients (37 with acute myeloid leukemia and 37 with acute lymphoblastic leukemia) will be accrued for this study.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
California
-
Duarte, California, Förenta staterna, 91010-3000
- City of Hope Comprehensive Cancer Center
-
Pasadena, California, Förenta staterna, 91030
- South Pasadena Cancer Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed acute myeloid leukemia or acute lymphoblastic leukemia (ALL)
- Relapsed or refractory disease
- Patients with Philadelphia chromosome-positive (Ph+) ALL refractory to BCR/ABL inhibitors are eligible
- Patients who have relapsed after prior autologous or allogenic stem cell transplant are eligible
- No active CNS disease
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Serum albumin ≥ 3 g/dL
- AST and ALT ≤ 2.5 times upper limit of normal (ULN) (5.0 times ULN if transaminase elevation is due to leukemic involvement)
- Bilirubin ≤ 1.5 times ULN
- Creatinine ≤ 1.5 times ULN or creatinine clearance ≥ 50 mL/min
- Potassium ≥ lower limit of normal (LLN)
- Phosphorous ≥ LLN
- Serum total calcium (corrected for serum albumin) or serum ionized calcium ≥ LLN
- Magnesium ≥ LLN
- Thyroid stimulating hormone and free T4 normal (thyroid hormone replacement therapy allowed)
- LVEF ≥ LLN by MUGA or ECHO
No impaired cardiac function, including any of the following:
- QTc > 450 msec
- Congenital long QT syndrome
- History of sustained ventricular tachycardia
- History of ventricular fibrillation or torsades de pointes
Bradycardia (i.e., heart rate < 50 beats per minute)
- Pacemaker allowed provided heart rate ≥ 50 beats per minute
- Myocardial infarction or unstable angina within the past 6 months
- New York Heart Association class III-IV congestive heart failure
- Right bundle branch block and left anterior hemiblock (bifascicular block)
- No uncontrolled hypertension
- No unresolved diarrhea > CTCAE grade 1
- No impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral panobinostat
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective double-barrier contraception during and for 3 months after completion of study treatment
- No other primary malignancy within the past 5 years, other than curatively treated carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin
- No HIV or hepatitis C positivity
- No other concurrent severe and/or uncontrolled medical condition
- No significant history of non-compliance to medical regimens or inability to give reliable informed consent
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Recovered from all prior therapy
- More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy
- More than 4 weeks since prior valproic acid
- No other prior treatment with a histone deacetylase inhibitor
- No concurrent medication that may cause QTc prolongation or induce torsades de pointes
- No concurrent CYP3A4 inhibitors
- No concurrent grapefruit, grapefruit juice, or Seville (sour) oranges
- No concurrent radiotherapy
- No other concurrent anticancer therapy or investigational therapy
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Treatment (panobinostat)
Patients receive oral panobinostat once on days 1, 3, and 5. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. panobinostat: 40 mg Monday, Wednesday and Friday of every week in a 28 day cycle |
40 mg Monday, Wednesday and Friday of every week in a 28 day cycle
Day 1 and day 28 samples
Day 1 and day 28 samples
Day 1 and day 28 samples
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Hematological Response Rate
Tidsram: Up to 6 cycles of treatment, up to 24 weeks.
|
Morphologic CR: morphologic leukemia-free state with absolute neutrophil count > 1000/uL and platelet count ≥ 100,000/uL and independent of blood transfusions.
Cytogenic CR: morphologic CR along with reversion to a normal karyotype by cytogenetic analysis.
Molecular CR: morphologic CR with no residual disease by molecular or flow cytometric detection methods.
Morphologic CR with incomplete blood recovery (CRi): morphologic CR except for residual neutropenia (<1000/uL) and/or thrombocytopenia (<1000,000/uL).
PR: same hematologic values for a CR but with a decrease of at least 50% in percentage of blasts to a post-treatment value of 5% to 25% in bone marrow aspirate.
(If the pre-treatment blast percentage was 50-100% this must decrease to a value between 5-25%.
If the pre-treatment blast percentage was 20-49% this must decrease by at least half to a value > 5%.)
A value ≤ 5% is also considered a PR if Auer rods are present.
Hematological response = morphologic CR+PR.
|
Up to 6 cycles of treatment, up to 24 weeks.
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Leslie Popplewell, MD, City of Hope Comprehensive Cancer Center
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Immunsystemets sjukdomar
- Neoplasmer efter histologisk typ
- Neoplasmer
- Lymfoproliferativa störningar
- Lymfatiska sjukdomar
- Immunproliferativa störningar
- Leukemi, lymfoid
- Leukemi
- Prekursorcellslymfoblastisk leukemi-lymfom
- Molekylära mekanismer för farmakologisk verkan
- Enzyminhibitorer
- Antineoplastiska medel
- Histon deacetylashämmare
- Panobinostat
Andra studie-ID-nummer
- 07174
- P30CA033572 (U.S.S. NIH-anslag/kontrakt)
- CHNMC-07174
- NOVARTIS-CHNMC-07174
- CDR0000601203 (Registeridentifierare: NCI PDQ)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Leukemi
-
Massachusetts General HospitalCelgene CorporationAvslutadAkut myelogen leukemi | Akut myeloid leukemi (AML) | Akut myelocytisk leukemi | Akut granulocytisk leukemi | Akut icke-lymfocytisk leukemiFörenta staterna
-
Institute of Hematology & Blood Diseases HospitalBejing Institute for Stem Cell and Regenerative Medicine; Institute for...RekryteringRefraktär leukemi | Återfallande leukemi | Akut myeloid leukemi, barndomKina
-
Hoffmann-La RocheAvslutadNeoplasmer, Myelogen leukemi, AkutFörenta staterna, Kanada
-
Genzyme, a Sanofi CompanyAvslutadAkut myelogen leukemiJapan
-
Betta Pharmaceuticals Co., Ltd.Har inte rekryterat ännuAkut Myeloid Leukemi LeukemiKina
-
Seagen Inc.AvslutadAkut myeloid leukemi | Akut myelogen leukemi | Akut promyelocytisk leukemiFörenta staterna
-
Massachusetts General HospitalAvslutad
-
Wyeth is now a wholly owned subsidiary of PfizerAvslutad
-
GlaxoSmithKlineAvslutadLeukemi, Myelocytisk, AkutFörenta staterna, Australien, Kanada
-
Hybrigenics CorporationOkändAkut myelogen leukemiFörenta staterna, Frankrike